MINI FUTURE LONG - LABORATORY CO. OF AMER. HLD | Market Closed - Börse Stuttgart 20:42:09 17/05/2024 BST | ||
| 3.63 EUR | -9.25% |
|
| Current month | +18.24% | ||
| 1 month | +21.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about LABORATORY CORPORATION OF AMERICA HOLDINGS
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 3.63 | -9.25% |
| 16/05/24 | 4 | +1.27% |
| 15/05/24 | 3.95 | +5.05% |
| 14/05/24 | 3.76 | -0.53% |
| 13/05/24 | 3.78 | +8.31% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 08:42 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | LABORATORY CORPORATION OF AMERICA HOLDINGS |
| Issuer | Morgan Stanley |
| WKN | MB1KRE |
| ISIN | DE000MB1KRE5 |
| Date issued | 19/12/2022 |
| Strike | 170.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.31 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.74 € |
|---|---|
| Lowest since issue | 1.81 € |
Company Profile
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows:
- clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services;
- development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies.
Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).
Sector
-
Ratings for Laboratory Corporation of America Holdings
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Laboratory Corporation of America Holdings
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
210.6
USD
Average target price
239.7
USD
Spread / Average Target
+13.81%
- Stock Market
- Certificates
- Certificat
